Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

2025-04-02 16:54:24 ET

Summary

• The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031.
• Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook for Edgewise Therapeutics, Inc. remains positive with multiple catalysts rapidly approaching for EWTX stock.
• Key milestones include 12-week data from the CIRRUS-HCM study in 2H 2025 and a phase 3 study initiation in 1H 2026.
• Besides Becker Muscular Dystrophy, sevasemten is also being explored for the treatment of patients with Duchenne Muscular Dystrophy.

The last time I wrote about Edgewise Therapeutics, Inc. ( EWTX ) it was in a Seeking Alpha article entitled " Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data . " In the article, I noted that the company had achieved positive results from its phase 2 CANYON study, which used its drug sevasemten for the treatment of patients with Becker Muscular Dystrophy [BMD]. This program is coming along well, especially since the company accomplished another milestone relating to this specific program, which was that it completed enrollment in the global pivotal phase 2 GRAND CANYON study using this drug to treat these patients....

Read the full article on Seeking Alpha

For further details see: